Mar 18, 2026 Articles, Diabetes, GLP- 1 Agonist Therapy Center, GLP-1 Agonist Therapy Center, Therapies, Type 2 Diabetes, Type 2 Diabetes 961 views Type 2 diabetes often feels like a slow-burning fire that gradually damages the body over time
When these elements work together, the overall experience feels confident, human, and sustainable rather than rushed or opaque
In clinical trials, tirzepatide reduced sleep apnea events by as much as two-thirds or about 66% over the course of 52 weeks in patients with obstructive sleep apnea
Taken together, these effects help explain why GLP-1 drugs have produced more durable weight loss than many earlier pharmacologic approaches, which often relied on stimulant-based appetite suppression or had limited tolerability
Tirzepatide is not indicated for type 1 diabetes
doi: 10.1179/135100009X392539 294 WilliamsB